Advertisement
Organisation › Details
Axovant Sciences (Nasdaq: AXON)
Axovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines to broadly address multiple forms of dementia and related neurological disorders. Axovant is developing a pipeline of product candidates that focuses on the cognitive, functional and behavioral aspects of debilitating conditions such as Alzheimer’s disease, Lewy body dementia and other neurological disorders. *
Start | 2017-08-11 existent | |
End | 2020-11-13 renamed before? | |
Group | Sio Gene Therapies Inc. (Nasdaq: SIOX) | |
Today | Sio Gene Therapies Inc. (Nasdaq: SIOX) | |
Industry | BIOTECH | |
Industry 2 | gene therapy | |
Person | Cheruvu, Pavan (Roivant 201806 CEO of Axovant Sciences) | |
Person 2 | Hung, David T. (Roivant Sciences 201704– CEO of Axovant before Medivation 201604 CEO) | |
Region | New York, NY | |
Country | United States (USA) | |
City | 10036 New York, NY | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Roivant Sciences GmbH. (9/26/17). "Press Release: Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer’s Disease". Basel. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Sio Gene Therapies Inc. (Nasdaq: SIOX)
- [1] Sio Gene Therapies Inc.. (1/31/22). "Press Release: Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition". New York, NY & Durham, NC....
- [2] Oxford Biomedica plc. (6/6/18). "Press Release: Oxford BioMedica and Axovant Sciences Enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease". Oxford....
- [3] Roivant Sciences GmbH. (9/26/17). "Press Release: Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer’s Disease". Basel....
- [4] Roivant Sciences GmbH. (9/26/17). "Press Release: Roivant Sciences Statement on MINDSET Results"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top